Format

Send to

Choose Destination
Low Urin Tract Symptoms. 2017 May;9(2):107-110. doi: 10.1111/luts.12113. Epub 2015 Sep 26.

Naftopidil Improves Symptoms in a Rat Model of Tranilast-Induced Interstitial Cystitis.

Author information

1
Southern Knights' Laboratory LLP, Okinawa, Japan.
2
Faculty of Medicine, The Institute for Animal Experiments, University of the Ryukyus, Okinawa, Japan.
3
Department of Biochemistry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

Abstract

OBJECTIVE:

The effect of naftopidil on symptoms of tranilast-induced interstitial cystitis (IC) was examined in rats.

METHODS:

Thirty-two female rats were divided into four groups (control, naftopidil, tranilast, and combination groups). Rats in the control group were fed a standard diet, while rats in the naftopidil, tranilast, and combination groups were fed diets containing naftopidil, tranilast, or naftopidil + tranilast, respectively. After 4 weeks of treatment, locomotor activity was measured and continuous cystometry was performed.

RESULTS:

During the light period, locomotor activity was lower in the tranilast group than in the control, naftopidil, and combination groups. During the dark period, locomotor activity was higher in the naftopidil group than in the other three groups. The combination group showed higher locomotor activity than the tranilast group, but significantly lower activity than the naftopidil group. Continuous cystometry revealed that the interval between bladder contractions was shorter in the tranilast group than in the other three groups. The combination group also had a shorter interval between contractions than the control group.

CONCLUSION:

Naftopidil improved the symptoms of tranilast-induced IC, such as reduced locomotor activity due to pelvic pain and a shortened interval between bladder contractions. Therefore, naftopidil may be a potential treatment for IC.

KEYWORDS:

interstitial cystitis; naftopidil; tranilast

PMID:
28394500
DOI:
10.1111/luts.12113
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center